Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2022

Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors

Andrew Dj. Pearson
Carl Allen
  • Fonction : Auteur
Jason Fangusaro
  • Fonction : Auteur
Susan Weiner
  • Fonction : Auteur
Gregory Reaman
  • Fonction : Auteur
Mark Russo
Sama Ahsan
  • Fonction : Auteur
Amy Barone
  • Fonction : Auteur
Elly Barry
Teresa de Rojas
Elizabeth Fox
Julia Glade Bender
Lia Gore
  • Fonction : Auteur
Doug Hawkins
Brent Kreider
Abraham Langseth
Giovanni Lesa
  • Fonction : Auteur
Franca Ligas
  • Fonction : Auteur
Kahina Nasri
  • Fonction : Auteur
Koen Norga
  • Fonction : Auteur
Karsten Nysom
Alberto Pappo
  • Fonction : Auteur
Gianluca Rossato
  • Fonction : Auteur
Nicole Scobie
Malcolm Smith
Elliot Stieglitz
Brenda Weigel
  • Fonction : Auteur
Amy Weinstein
  • Fonction : Auteur
Ruth Viana
  • Fonction : Auteur
Dominik Karres
  • Fonction : Auteur

Résumé

Background: In developed countries, cancer remains the leading cause of pediatric death from illness after the neonatal period. Objective: To describe the end-of-life care characteristics of children and adolescents with solid tumors (ST) or hematologic malignancies (HM) who died from tumor progression in the Île-de-France area. Methods: This is a regional, multicentric, retrospective review of medical files of all children and adolescents with cancer who died over a 1-year period. Extensive data from the last 3 months of life were collected. Results: A total of 99 eligible patients died at a median age of 9.8 years (range, 0.3–24 years). The most frequent terminal symptoms were pain (n = 86), fatigue (n = 84), dyspnea (n = 49), and anorexia (n = 41). Median number of medications per patient was 8 (range, 3–18). Patients required administration of opioids (n = 91), oxygen (n = 36), and/or sedation (n = 61). Decision for palliative care was present in all medical records and do-not-resuscitate orders in 90/99 cases. Symptom prevalence was comparable between children and adolescents with ST and HM. A wish regarding the place of death had been expressed for 64 patients and could be respected in 42 cases. Death occurred in hospital for 75 patients. Conclusions: This study represents a large and informative cohort illustrating current pediatric palliative care approaches in pediatric oncology. End-of-life remains an active period of care requiring coordination of multiple care teams.

Dates et versions

hal-04493113 , version 1 (06-03-2024)

Identifiants

Citer

Andrew Dj. Pearson, Carl Allen, Jason Fangusaro, Caroline Hutter, Olaf Witt, et al.. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors. European Journal of Cancer, 2022, 177 (3), pp.120-142. ⟨10.1016/j.ejca.2022.09.036⟩. ⟨hal-04493113⟩
8 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More